DE4021517B4 - Formulierungen mit verlangsamter Freisetzung wasserlöslicher Peptide - Google Patents

Formulierungen mit verlangsamter Freisetzung wasserlöslicher Peptide Download PDF

Info

Publication number
DE4021517B4
DE4021517B4 DE4021517A DE4021517A DE4021517B4 DE 4021517 B4 DE4021517 B4 DE 4021517B4 DE 4021517 A DE4021517 A DE 4021517A DE 4021517 A DE4021517 A DE 4021517A DE 4021517 B4 DE4021517 B4 DE 4021517B4
Authority
DE
Germany
Prior art keywords
formulation
cys
slow release
thr
glycolide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE4021517A
Other languages
German (de)
English (en)
Other versions
DE4021517A1 (de
Inventor
David Dr. Bodmer
Jones W. Fong
Thomas Dr. Kissel
Hawkins V. Maulding
Oskar Nagele
Jane E. Pearson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to DE4042752A priority Critical patent/DE4042752B4/de
Publication of DE4021517A1 publication Critical patent/DE4021517A1/de
Application granted granted Critical
Publication of DE4021517B4 publication Critical patent/DE4021517B4/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE4021517A 1989-07-07 1990-07-06 Formulierungen mit verlangsamter Freisetzung wasserlöslicher Peptide Expired - Lifetime DE4021517B4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE4042752A DE4042752B4 (de) 1989-07-07 1990-07-06 Verfahren zur Herstellung von Mikropartikeln, welche einen Wirkstoff in einem bioabbaubaren polymeren Träger enthalten

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US37702389A 1989-07-07 1989-07-07
US377023 1989-07-07
US41134789A 1989-09-22 1989-09-22
US411347 1989-09-22
DE4042746 1990-07-06
DE4042753 1990-07-06
DE4042752A DE4042752B4 (de) 1989-07-07 1990-07-06 Verfahren zur Herstellung von Mikropartikeln, welche einen Wirkstoff in einem bioabbaubaren polymeren Träger enthalten

Publications (2)

Publication Number Publication Date
DE4021517A1 DE4021517A1 (de) 1991-01-17
DE4021517B4 true DE4021517B4 (de) 2009-04-09

Family

ID=27007654

Family Applications (2)

Application Number Title Priority Date Filing Date
DE4042752A Expired - Lifetime DE4042752B4 (de) 1989-07-07 1990-07-06 Verfahren zur Herstellung von Mikropartikeln, welche einen Wirkstoff in einem bioabbaubaren polymeren Träger enthalten
DE4021517A Expired - Lifetime DE4021517B4 (de) 1989-07-07 1990-07-06 Formulierungen mit verlangsamter Freisetzung wasserlöslicher Peptide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE4042752A Expired - Lifetime DE4042752B4 (de) 1989-07-07 1990-07-06 Verfahren zur Herstellung von Mikropartikeln, welche einen Wirkstoff in einem bioabbaubaren polymeren Träger enthalten

Country Status (27)

Country Link
JP (5) JPH0832624B2 (es)
KR (2) KR100303681B1 (es)
AT (1) AT406225B (es)
AU (2) AU641407B2 (es)
BE (1) BE1004486A3 (es)
CA (1) CA2020477C (es)
CH (1) CH685230A5 (es)
CY (1) CY1965A (es)
DE (2) DE4042752B4 (es)
DK (1) DK175849B1 (es)
FI (3) FI108611B (es)
FR (1) FR2649319A1 (es)
GB (2) GB2234896B (es)
GR (1) GR1001121B (es)
HK (2) HK97695A (es)
HU (2) HU221294B1 (es)
IE (2) IE64216B1 (es)
IL (3) IL94983A (es)
IT (1) IT1241460B (es)
LU (1) LU87764A1 (es)
MY (1) MY106722A (es)
NL (1) NL195027C (es)
NO (2) NO302928B1 (es)
NZ (1) NZ234384A (es)
PT (1) PT94628B (es)
SE (1) SE512992C2 (es)
SG (1) SG26416G (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
YU48420B (sh) * 1991-03-25 1998-07-10 Hoechst Aktiengesellschaft Postupak za dobijanje biološki razgradljivih mikročestica sa dugotrajnim delovanjem
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
DE4218510A1 (de) * 1992-06-02 1993-12-09 Pharmatech Gmbh Verfahren zur Herstellung biologisch abbaubarer Polyester
AU4198793A (en) † 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
EP0626170A3 (en) * 1993-05-10 1996-03-27 Sandoz Ltd Stabilization of pharmacoligically active compounds in controlled release compositions.
GB9310781D0 (en) * 1993-05-25 1993-07-14 Davis Stanley S Preparation of microparticles
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
DK0729357T3 (da) 1993-11-19 2005-06-06 Janssen Pharmaceutica Nv Mikroindkapslede 1,2-benzazoler
EP0862419B2 (en) 1995-11-09 2010-11-17 Microbiological Research Authority Microencapsulated dna for vaccination and gene therapy
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6632457B1 (en) * 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6226656B1 (en) 1998-11-12 2001-05-01 Sourcefinder, Inc. System and method for creating, generating and processing user-defined generic specs
US7107268B1 (en) 1998-11-12 2006-09-12 Printable Technologies, Inc. Centralized system and method for managing enterprise operations
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
EP1044683A1 (en) * 1999-04-15 2000-10-18 Debio Recherche Pharmaceutique S.A. One-step dispersion method for the microencapsulation of water soluble substances
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
KR100392501B1 (ko) * 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
JP2004516262A (ja) 2000-12-21 2004-06-03 ネクター セラピューティクス 親水性活性剤を含有するマイクロ粒子の製造のための誘発相転移法
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
PE20050285A1 (es) * 2003-06-24 2005-06-09 Novartis Ag Composicion farmaceutica que comprende analogos ciclicos de somatostatina
JP2008518881A (ja) * 2003-07-18 2008-06-05 オークウッド ラボラトリーズ，エル．エル．シー． 高分子組成物中の高分子の分子量低下、不純物形成およびゲル化の防止
MY158342A (en) 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
JPWO2005082405A1 (ja) * 2004-02-26 2007-10-25 独立行政法人科学技術振興機構 たんぱく性薬物の注射用徐放性微粒子製剤およびその製造法
DE102004053373A1 (de) * 2004-11-02 2006-05-04 Justus-Liebig-Universität Giessen Erfindung betreffend anisometrische Partikel in Form von Nano-/Meso-Fasern -Röhren, -Kabeln -Bändern und deren gekrümmte oder verzweigte Abwandlungen
KR100741867B1 (ko) * 2005-07-05 2007-07-24 전북대학교산학협력단 수중유적 및 용매 증발법을 이용한 이중층 미립구의제조방법
KR20130024987A (ko) * 2005-12-22 2013-03-08 노파르티스 아게 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
KR100816065B1 (ko) * 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
CA2713339C (en) 2008-01-30 2017-01-17 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
CA2813301A1 (en) * 2010-09-30 2012-04-05 Evonik Corporation Method for removing residual organic solvent from microparticles
WO2012044675A2 (en) * 2010-09-30 2012-04-05 Surmodics Pharmaceuticals, Inc. Emulsion method for preparing low residual solvent microparticles
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
KR102464650B1 (ko) 2016-05-03 2022-11-10 엘에스일렉트릭(주) 배선용 차단기의 한류장치
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0029579A1 (en) * 1979-11-27 1981-06-03 Sandoz Ag Polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use
EP0203031A2 (en) * 1985-04-25 1986-11-26 The Administrators of The Tulane University Educational Fund Biologically active lysine containing octapeptides

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CH649217A5 (de) * 1977-08-25 1985-05-15 Sandoz Ag Bromocriptin enthaltende mikrokapseln.
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3378250D1 (en) * 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
US4485101A (en) * 1983-10-11 1984-11-27 Administrators Of The Tulane Educational Fund Peptides
JPH0657658B2 (ja) * 1985-04-11 1994-08-03 住友製薬株式会社 徐放性製剤
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8331158D0 (en) * 1983-11-22 1983-12-29 British Telecomm Metal/semiconductor deposition
JPS60181029A (ja) * 1984-02-29 1985-09-14 Toyo Jozo Co Ltd 徐放性製剤の製法
CH660302A5 (fr) * 1984-10-17 1987-04-15 Debiopharm Sa Procede de micro-encapsulation en phase heterogene de substances medicamenteuses hydrosolubles.
DE3678308D1 (de) * 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
CH665558A5 (en) * 1985-10-09 1988-05-31 Debiopharm Sa Phase sepn. prodn. of microcapsules for water soluble pharmaceuticals - using fluoro-substd. aliphatic hydrocarbon as non-solvent in the hardening stage
JP2539789B2 (ja) * 1986-03-06 1996-10-02 日本原子力研究所 ポリラクトンからなる徐放性薬物複合体の製造方法
GB2193891B (en) * 1986-08-18 1990-07-25 Sandoz Ltd Nasal pharmaceutical composition containing a somatostatin anologue.
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH672887A5 (es) * 1987-10-14 1990-01-15 Debiopharm Sa
DE3738228A1 (de) * 1987-11-11 1989-05-24 Hoechst Ag Verfahren zur herstellung von bioabbaubaren mikrokapseln wasserloeslicher peptide und proteine sowie nach diesem verfahren erhaltene mikrokapseln
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0029579A1 (en) * 1979-11-27 1981-06-03 Sandoz Ag Polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use
US4395403A (en) * 1979-11-27 1983-07-26 Sandoz Ltd. Polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use
EP0203031A2 (en) * 1985-04-25 1986-11-26 The Administrators of The Tulane University Educational Fund Biologically active lysine containing octapeptides

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CAI, R.Z., SZOKE, B., LU, R., [u.a.]: Synthesis and biological activity of highly potent octapeptide analogs of somstostatin. 1986, In: Proc. Natl. Acad. Sci. USA, Vol. 83, S. 1896-1900 *
Internet Rech. am 23.10.02, http://www.ncbi.nlm. nih.gov/entrez *
Medline abstr., PMID:2869490 *
RÖMPP: Chemie-Lexikon, 8. Aufl., 1981, S. 1123 *
RÖMPP: Chemie-Lexikon, 8. Aufl., 1981, S. 1123; In ternet Rech. am 23.10.02, http://www.ncbi.nlm. nih .gov/entrez CAI, R.Z., SZOKE, B., LU, R., [u.a.]: Synthesis and biological activity of highly potent octapeptide analogs of somstostatin. 1986, In: Pr oc. Natl. Acad. Sci. USA, Vol. 83, S. 1896-1900. M edline Abstr., PMID:2869490.

Also Published As

Publication number Publication date
AU5874690A (en) 1991-01-10
GB2265311A (en) 1993-09-29
DK175849B1 (da) 2005-03-29
GR900100513A (en) 1991-12-10
NO302928B1 (no) 1998-05-11
HUT54037A (en) 1991-01-28
FR2649319B1 (es) 1994-12-09
DK162590D0 (da) 1990-07-05
CA2020477C (en) 2000-11-21
JPH07285853A (ja) 1995-10-31
IE64411B1 (en) 1995-08-09
FR2649319A1 (fr) 1991-01-11
SE9002364L (sv) 1991-01-08
PT94628A (pt) 1991-03-20
JPH08198771A (ja) 1996-08-06
NO903001D0 (no) 1990-07-05
GB2234896B (en) 1994-01-19
JP2001233897A (ja) 2001-08-28
AU687553B2 (en) 1998-02-26
KR100303681B1 (ko) 2002-05-16
NL195027B (nl) 2003-08-01
IT1241460B (it) 1994-01-17
IL94983A (en) 1999-08-17
CY1965A (en) 1997-07-04
SG26416G (en) 1995-09-01
JP2931773B2 (ja) 1999-08-09
HU221294B1 (en) 2002-09-28
ATA144090A (de) 1999-08-15
AT406225B (de) 2000-03-27
JPH07309897A (ja) 1995-11-28
GB9014704D0 (en) 1990-08-22
JPH0368511A (ja) 1991-03-25
NL195027C (nl) 2003-12-02
NO983923D0 (no) 1998-08-26
SE512992C2 (sv) 2000-06-12
FI20000059A (fi) 2000-01-12
SE9002364D0 (sv) 1990-07-05
NO983923L (no) 1991-01-08
CA2020477A1 (en) 1991-01-08
FI109334B (fi) 2002-07-15
BE1004486A3 (fr) 1992-12-01
IL131880A (en) 2001-12-23
GB2234896A (en) 1991-02-20
KR910002430A (ko) 1991-02-25
IT9048113A1 (it) 1992-01-05
DE4042752B4 (de) 2009-05-07
NO320444B1 (no) 2005-12-05
DK162590A (da) 1991-01-08
HK97695A (en) 1995-06-23
AU2332195A (en) 1995-09-07
FI108611B (fi) 2002-02-28
NO903001L (no) 1991-01-08
IL94983A0 (en) 1991-06-10
IE902435A1 (en) 1991-02-13
JPH0832624B2 (ja) 1996-03-29
HU211602A9 (en) 1995-12-28
NL9001537A (nl) 1991-02-01
IE64216B1 (en) 1995-07-26
FI903429A0 (fi) 1990-07-06
HU903974D0 (en) 1990-11-28
CH685230A5 (de) 1995-05-15
LU87764A1 (fr) 1992-03-11
FI109543B (fi) 2002-08-30
PT94628B (pt) 1997-06-30
MY106722A (en) 1995-07-31
FI20000060A (fi) 2000-01-12
AU641407B2 (en) 1993-09-23
DE4021517A1 (de) 1991-01-17
HK197496A (en) 1996-11-08
IT9048113A0 (it) 1990-07-05
GB9306204D0 (en) 1993-05-19
GB2265311B (en) 1994-02-09
GR1001121B (el) 1993-04-28
IL131881A (en) 2001-12-23
KR100442931B1 (ko) 2004-08-02
NZ234384A (en) 1994-05-26

Similar Documents

Publication Publication Date Title
DE4021517B4 (de) Formulierungen mit verlangsamter Freisetzung wasserlöslicher Peptide
DE69914787T2 (de) Flüssige zusammensetzungen mit kontrollierter freigabe mit niedrigem initialfreisetzungsstoss des wirkstoffs
EP0797609B1 (de) Polyester
DE69828252T2 (de) Zusammensetzung mit verzögerter freisetzung, wobei medikamente in mikropartikel aus hyaluronsäure eingekapselt sind
DE69730093T2 (de) Zubereitung mit verzögerter Freisetzung
EP0814778B1 (de) Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung
DE69329295T2 (de) Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung
DE69937576T2 (de) Bioabbaubare niedermolekulare triblock-polyester-polyethylenglykol-copolymere mit umgekehrter thermischer gelierung
DE69829204T2 (de) Biologisch abbaubare triblock-poly(lactide-co-glycolide)-polyethylenglycol-copolymere mit umgekehrter thermischer gelierung
DE60111068T2 (de) Polymere verabreichungsform von leuprolid mit verbesserter wirksamkeit
DE69633399T2 (de) Verlängerte freisetzung von gm-csf
AT408609B (de) Zubereitung zur stetigen und kontrollierten abgabe von medikamentösen substanzen und verfahren zu deren herstellung
DE68904326T3 (de) Physiologisch aktive Substanzen enthaltende Mikrosphären des Polymilchsäuretyps sowie Verfahren zu deren Herstellung.
DE3853853T2 (de) Verabreichungsformen für Pharmaka.
AT397035B (de) Bioerodierbare pharmazeutische zusammensetzung für anhaltende und kontrollierte polypeptid-wirkstofffreigabe
DE69333817T2 (de) Leuprorelinpräparat mit verzögerter Wirkstoffabgabe
DE2842088A1 (de) Arzneimittel mit verzoegerter wirkstoffabgabe
EP0938342B1 (de) Injizierbare polymerzusammensetzung zur herstellung eines in-situ-implantats
DE69932201T2 (de) Emulsionen für in-situ Arzneistoffabgabesysteme
DE60220796T2 (de) Positiv geladenes amphiphiles blockcopolymer als arzneistoffträger und komplex davon mit negativ geladenem arzneistoff
EP0315875A1 (de) Verfahren zur Herstellung von bioabbaubaren Mikrokapseln wasserlöslicher Peptide und Proteine sowie nach diesem Verfahren erhaltene Mikrokapseln
DE19712718A1 (de) Immobilisierte und aktivitätsstabilisierte Komplexe von LHRH-Antagonisten und Verfahren zu deren Herstellung
DE3782117T2 (de) Verkapselung von trh bzw. dessen analoga.
DE2842089A1 (de) Arzneimittel mit verzoegerter wirkstoffabgabe
DE69203551T2 (de) Biologisch abbaubarer Copolyester von 4-Hydroxyprolin und diesen enthaltende pharmazeutische Zusammensetzung.

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8127 New person/name/address of the applicant

Owner name: NOVARTIS AG, BASEL, CH

8128 New person/name/address of the agent

Representative=s name: SPOTT WEINMILLER & PARTNER, 80336 MUENCHEN

8125 Change of the main classification

Ipc: A61K 38/31

8172 Supplementary division/partition in:

Ref document number: 4042746

Country of ref document: DE

Kind code of ref document: P

Q171 Divided out to:

Ref document number: 4042746

Country of ref document: DE

Kind code of ref document: P

8172 Supplementary division/partition in:

Ref document number: 4042752

Country of ref document: DE

Kind code of ref document: P

Ref document number: 4042753

Country of ref document: DE

Kind code of ref document: P

Q171 Divided out to:

Ref document number: 4042753

Country of ref document: DE

Kind code of ref document: P

Ref document number: 4042752

Country of ref document: DE

Kind code of ref document: P

AH Division in

Ref document number: 4042753

Country of ref document: DE

Kind code of ref document: P

Ref document number: 4042752

Country of ref document: DE

Kind code of ref document: P

Ref document number: 4042746

Country of ref document: DE

Kind code of ref document: P

8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336